Related Experiment Video
Updated: Jun 9, 2026

Confocal Imaging of Double-Stranded RNA and Pattern Recognition Receptors in Negative-Sense RNA Virus Infection
Published on: January 26, 2019
Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing
Alina Baum1, Ravi Sachidanandam, Adolfo García-Sastre
1Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029, USA.
Abstract:
Intracellular detection of virus infections is a critical component of innate immunity carried out by molecules known as pathogen recognition receptors (PRRs). Activation of PRRs by their respective pathogen-associated molecular patterns (PAMPs) leads to production of proinflamatory cytokines, including type I IFN, and the establishment of an antiviral state in the host. Out of all PRRs found to date, retinoic acid inducible gene I (RIG-I) has been shown to play a key role in recognition of RNA viruses. On the basis of in vitro and transfection studies, 5'ppp RNA produced during virus replication is thought to bind and activate this important sensor. However, the nature of RNA molecules that interact with endogenous RIG-I during the course of viral infection has not been determined. In this work we use next-generation RNA sequencing to show that RIG-I preferentially associates with shorter, 5'ppp containing viral RNA molecules in infected cells. We found that during Sendai infection RIG-I specifically bound the genome of the defective interfering (DI) particle and did not bind the full-length virus genome or any other viral RNAs. In influenza-infected cells RIG-I preferentially associated with shorter genomic segments as well as subgenomic DI particles. Our analysis for the first time identifies RIG-I PAMPs under natural infection conditions and implies that full-length genomes of single segmented RNA virus families are not bound by RIG-I during infection.
Insights
Retinoic acid inducible gene I (RIG-I) preferentially binds shorter, 5'ppp viral RNA fragments during infection. This pathogen recognition receptor (PRR) sensor targets defective interfering particles, not full-length viral genomes.
Area of Science:
- Immunology
- Virology
- Molecular Biology
Background:
- Innate immunity relies on pathogen recognition receptors (PRRs) to detect intracellular virus infections.
- Retinoic acid inducible gene I (RIG-I) is a key PRR for recognizing RNA viruses.
- The exact viral RNA molecules activating RIG-I during natural infections remain unclear.
Purpose of the Study:
- To identify the specific viral RNA molecules that interact with endogenous RIG-I during viral infections.
- To characterize the PAMPs (pathogen-associated molecular patterns) recognized by RIG-I under natural infection conditions.
Main Methods:
- Utilized next-generation RNA sequencing to analyze RNA-RIG-I interactions in infected cells.
- Investigated RIG-I binding preferences during Sendai and influenza virus infections.
Main Results:
- RIG-I preferentially associates with shorter, 5'ppp-containing viral RNA molecules.
- During Sendai infection, RIG-I specifically bound defective interfering (DI) particle genomes, excluding full-length viral RNA.
- In influenza-infected cells, RIG-I associated with shorter genomic segments and subgenomic DI particles.
Conclusions:
- This study identifies RIG-I PAMPs under natural infection conditions for the first time.
- Full-length genomes of single-segmented RNA viruses are likely not bound by RIG-I during infection.
- RIG-I's preference for shorter viral RNAs, including DI particles, highlights a specific mechanism in innate antiviral immunity.
Related Concept Videos
RNA-seq
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while microarray-based...
Viruses with RNA Genomes
Leaky Scanning
Experimental RNAi
Size and Structure of Viral Genomes
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
